Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Lip, GYH; Nikorowitsch, J; Sehner, S; Becher, N; Bertaglia, E; Blomstrom-Lundqvist, C; Brandes, A; Beuger, V; Calvert, M; Camm, AJ; Chlouverakis, G; Dan, GA; Dichtl, W; Diener, HC; Fierenz, A; Goette, A; de, Groot, JR; Hermans, A; Lubinski, A; Marijon, E; Merkely, B; Mont, L; Ozga, AK; Rajappan, K; Sarkozy, A; Scherr, D; Schnabel, RB; Schotten, U; Simantirakis, E; Toennis, T; Vardas, P; Wichterle, D; Zapf, A; Kirchhof, P.
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.
Eur Heart J. 2024; 45(19):1733-1737
Doi: 10.1093/eurheartj/ehae225
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Scherr Daniel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Atrial Fibrillation - drug therapy, complications
- Anticoagulants - administration & dosage, therapeutic use
- Female - administration & dosage
- Male - administration & dosage
- Administration, Oral - administration & dosage
- Age Factors - administration & dosage
- Aged - administration & dosage
- Sex Factors - administration & dosage
- Stroke - prevention & control, epidemiology
- Comorbidity - administration & dosage
- Treatment Outcome - administration & dosage
- Cardiovascular Diseases - prevention & control, epidemiology
- Find related publications in this database (Keywords)
- Atrial high-rate episodes
- Device-detected atrial fibrillation
- Stroke
- Atrial fibrillation
- CHA2DS2-VASc score
- Kidney function
- NOAH-AFNET 6
- Anticoagulation
- Bleeding